FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vasimigton,	D.O.	200-0

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPI	OMB APPROVAL								
	OMB Number:	3235-0287								
	Estimated average burden									
- 1	hours nor rosponso:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Granger Elder					2. Issuer Name and Ticker or Trading Symbol Better Therapeutics, Inc. [BTTX]										ionship of Reporti all applicable) Director		10%		Owner
(Last) (First) (Middle) C/O BETTER THERAPEUTICS, INC. 548 MARKET STREET, #49404				3. Date of Earliest Transaction (Month/Day/Year) 11/10/2021										below)	(give title		Other (s below)		
(Street) SAN FRANCI			94104 (Zip)		4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								Indivine)	,				
		Tab	le I - Non-	Deriva	ative	e Se	curities	s Ac	quired,	Dis	posed o	f, or Be	neficia	lly (Dwned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date		Code (I	4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)		tr. 3, 4 ar	4 and Securitie Benefici Owned F		es Forn ally (D) o Following (I) (Ir		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	ate, Tr	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		De Se	rivative (curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Co	ode	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$10.14	11/10/2021			A		28,300		(1)	1	1/09/2031	Common Stock	28,300		\$0.00	28,300	0	D	

Explanation of Responses:

1. The stock option vests as to 1/3 of the shares subject to the stock option on November 10, 2022 and the remaining shares vest in 24 equal monthly installments thereafter; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors of the Issuer or otherwise ceases to serve as a director of the Issuer prior to any such vesting date. The stock option shall accelerate pursuant to the terms of the Non-Employee Director Compensation Policy of the Issuer. The stock option was granted on November 10, 2021.

Remarks:

/s/ Mark Heinen, Attorney-in-

11/15/2021

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.